1. |
|
2. |
|
3. |
|
4. |
|
5. |
|
6. |
|
7. |
|
8. |
|
9. |
Seebacher V, Polterauer S, Grimm C, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial. Br J Cancer, 2010, 102(6): 952-956.
|
10. |
|
11. |
Tani Y, Kaneda H, Koh Y, et al. The impact of estrogen receptor expression on mutational status in the evolution of non-small cell lung cancer. Clin Lung Cancer, 2023, 24(2): 165-174.
|
12. |
|
13. |
|
14. |
|
15. |
|
16. |
Ciriaco P, Carretta A, Calori G, et al. Lung resection for cancer in patients with coronary arterial disease: Analysis of short-term results. Eur J Cardiothorac Surg, 2002, 22(1): 35-40.
|
17. |
|
18. |
Dardzińska JA, Małgorzewicz S, Szupryczyńska N, et al. Adherence to the 2021 dietary guidelines of the European Society of Cardiology on cardiovascular disease prevention in residents of the Pomeranian Voivodeship with increased cardiovascular risk. Pol Arch Intern Med, 2023, 133(6): 16418.
|
19. |
Sun M, Yang Q, Li M, et al. Association between the severity of coronary artery disease and lung cancer: A pilot cross-sectional study. Arq Bras Cardiol, 2022, 118(2): 478-485.
|
20. |
郭凡. 非小细胞肺癌合并冠心病行同期手术治疗的研究. 天津医科大学, 2020.Guo F. Combined surgery in patients with nonsmall cell lung cancer accompanied bycoronary artery disease. Tianjin Medical University, 2020.
|
21. |
|
22. |
Tourmousoglou CE, Apostolakis E, Dougenis D. Simultaneous occurrence of coronary artery disease and lung cancer: What is the best surgical treatment strategy? Interact Cardiovasc Thorac Surg, 2014, 19(4): 673-681.
|
23. |
|
24. |
|
25. |
|
26. |
|
27. |
|
28. |
|
29. |
Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage ⅢB/Ⅳ non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase Ⅱ study. J Clin Oncol, 2012, 30(17): 2046-2054.
|
30. |
Meng Y, Li L, Wang H, et al. Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: A case report. Ann Transl Med, 2022, 10(8): 496.
|
31. |
Hu X, Shui Y, Hirano H, et al. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunol Immunother, 2023, 72(3): 719-731.
|
32. |
Alduais Y, Zhang H, Fan F, et al. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine (Baltimore), 2023, 102(8): e32899.
|
33. |
Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(12): 1441-1464.
|
34. |
Markovic M, Mitrovic S, Dagovic A, et al. Does the expression of vascular endothelial growth factor (VEGF) and Bcl-2 have a prognostic significance in advanced non-small cell lung cancer? Healthcare (Basel), 2023, 11(3): 292.
|